Investor Presentation • Nov 30, 2010
Investor Presentation
Open in ViewerOpens in native device viewer
Frankfurt am Main, November 23, 2010
This presentation contains forward-looking statements and information – that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will" or words of similar meaning meaning. Such statements are based on current expectations and certain assumptions of the management of MeVis Group, and are, therefore, subject to certain risks and uncertainties. A variety of factors, many of which are beyond MeVis Medical Solutions AG's control, affect its operations, performance, business strategy and results and could cause the actual results, performance or achievements of MeVis Medical Solutions AG worldwide to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Among the factors and risks that could cause actual results to differ materially from those described in the forward-looking statements are in particular changes in global, political, economic, exchange rate, business, competitive, market and regulatory forces. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the relevant forward-looking statement as anticipated, believed, estimated, expected, intended, planned or projected. MeVis Medical Solutions AG does not intend or assume any obligation to update or revise these forward forward-looking lookingstatements in light of developments which differ from those anticipated. Also, no representation or warranty (express or implied) is made to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein.
This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom, or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i) (ii) and (iii) above together being referred to as "relevant persons") (i), persons").
→
→ Challenging market environment remaining for new O.D. products, especially for Lung CAD business
→Group EBIT increases by 182%
* Excluding inter-segment revenues. ** Including adjustments in Q3/2009.
November 23, 2010 German Equity Forum Dr. Carl J.G. Evertsz 4
© Siemens AG
→ Enhanced workflow efficiency opening up possibilities for use by physicians in private practices
→ Successful leverage of Hologic's installed base & global infrastructure
MeVis Medical Solutions AG
November 23, 2010 German Equity Forum 5
→Performance of M3V stock in Q3/2010: -5% (SDAX +14% / TecDAX +9%)
→Approximately € 14 million group revenues with slightly negative EBIT
M di l l dd d th hedical valueadded through:
November 23, 2010 German Equity Forum Dr. Carl J.G. Evertsz 9
"Leading independent manufacturer and vendor of dedicated medical imaging software with focus on disease-oriented clinical applications."
BUSINESS UPDATE – VALUE-BASED APPROACH TO STRATEGIC MANAGEMENTPenetration of existing markets Breast (2/3)
Further development of existing products
Example:
Digital Mammography Workstation for Hologic
→Significant product improvements
* Fiscal 2009: € 2.3 million.
November 23, 2010 German Equity Forum 12
BUSINESS UPDATE – VALUE-BASED APPROACH TO STRATEGIC MANAGEMENTPenetration of existing markets Breast (3/3)
Example:
Automated Fullfield Breast Ultrasound
Market introductions 2009/10
* Consolidation quote: 51%.
November 23, 2010 German Equity Forum 13
BUSINESS UPDATE – VALUE-BASED APPROACH TO STRATEGIC MANAGEMENT
Development of new markets Focus: "Other Diagnostics" Segment
Sales chanel
New product development with focus on:
* Under development.
€ 1.5m estimated revenues contribution in fiscal 2010 from products, which were developed subsequent to IPO (11% of total Group revenues)
* Not included are regular product upgrade releases.
November 23, 2010 German Equity Forum 15
MeVis Medical Solutions AG
November 23, 2010 German Equity Forum Dr. Carl J.G. Evertsz 16
→ Cardio-vascular imaging is set to become a main growth driver for MeVisGroup subsequent to expected complete take over in Q2/2011
* Valued at € 19.60.
November 23, 2010 German Equity Forum 18
→
| ig in ( ) F E U R 0 0 0 S I F R S ur es |
/ 9 M 0 9 |
/ 9 M 1 0 |
∆ in % |
|---|---|---|---|
| Re ve nu es |
1 0, 2 6 9 |
1 0, 9 0 3 |
6 % |
| l h hy D ig ita Ma Ma m m m m og og ra ap p |
7 5 , 4 4 |
8 0 , 2 3 |
1 1 % |
| Ot he D iag ics st r no |
2, 8 2 5 |
2, 6 7 7 |
-5 % |
| Eu ro |
3 1, 1 1 |
0 1, 7 1 |
3 % 5 |
| l lar U S- Do |
9, 1 5 6 |
9, 2 0 2 |
1 % |
| In fr he i l iza io f de lo t ta t t co m e om ap n o ve p m en ex p en se s c |
1, 7 4 8 |
2, 1 6 3 |
2 4 % |
| O he in in t t r o p er a g co m e |
1, 2 9 2 |
1, 0 1 7 |
-2 1 % |
| f m f s Co ia ls / ice ha d t te t s o a co s o er s p c se r v ur |
0, 4 3 0 - |
0, 4 0 4 - |
6 % |
| f f c S ta ts os |
-7 7 4 2 , |
7, 9 8 6 - |
3 % |
| he O t t io r o p er a n ex p en se s |
-2 5 3 1 , |
2, 2 2 3 - |
-1 2 % |
| E B I T D A |
2, 6 0 6 |
3, 4 7 0 |
3 3 % |
| d De ia t io t iza t io p re c n an am or n |
8 -1 9 3 , |
2, 6 3 6 - |
3 9 % |
| he f: b le t int i ts re o an g as se |
-0 9 , 8 5 |
-0 3 , 9 4 |
1 0 % |
| he f: l d de lop t ita ize t e re o p ve m en xp en se ca s |
-0 6 1 1 , |
1, 3 4 5 - |
1 2 0 % |
| he f: lan & ip t ty, t t re o p ro p er p eq u m en |
-0 4 2 3 , |
0, 3 4 8 - |
8 % -1 |
| E B I T |
0, 7 1 3 |
0, 8 3 4 |
1 7 % |
| In te t in re s co m e |
0, 5 4 4 |
0, 3 4 1 |
-3 7 % |
| In te t re s ex p en se s |
-0 2 7 4 , |
0, 5 7 1 - |
2 3 % |
| O he f in ia l r l t t t r ne an c es u |
0, 0 5 5 |
0, 1 4 4 |
6 2 % 1 |
| f i ha fr ia d ie Pr t s te o re om a ss oc co m p an s |
0, 0 0 0 |
0, 0 7 4 - |
n. a. |
| N f in ia l r l t t e an c es u |
-0 1 4 3 , |
0, 1 6 0 - |
1 2 % |
| E B T |
0, 5 7 0 |
0, 6 7 4 |
1 8 % |
| In ta co m e ex p en se x |
-0 2 9 8 , |
1, 0 2 0 - |
2 4 2 % |
| l l i i d da d d f f i i f fo h he i io d d Co te t t t ns o ne p ro r p er |
0, 2 7 2 |
0, 3 4 6 - |
-2 2 7 % |
| in ha Ea rn g s p er s re |
0, 1 6 € |
-0 2 0 € , |
-2 2 8 % |
| h d ha d ba d d lu d W ig te ts ta in ic i te e av er ag e co m m on s re s ou n g s an - |
1. 7 1 1. 3 9 7 |
1. 7 0 0. 9 6 5 |
|
| E B I T D A in -m ar g |
2 % 5 |
3 2 % |
|
| S M M E B I T- in m ar g |
% 7 |
8 % |
|
| in in E E B B T T- m m ar ar g g |
6 % |
6 % |
|
MeVis Medical Solutions AG
November 23, 2010 German Equity Forum 21
Dr. Robert Hannemann
→ Group profitability stron gly depends on capitalization balance of development expenses
| ig in ( ) F E U R 0 0 0 S I F R S ur es |
D 3 1, 2 0 0 9 ec |
Se 3 0, 2 0 1 0 p. |
∆ in % |
|---|---|---|---|
| N t t ts on -c cu ur rr re en n as se |
2 9 8 3 7 |
3 0 8 1 4 . |
% 4 |
| b le In ta i ts ng a ss e |
2 0 9 7. 5 |
2 0 7. 4 7 |
% 1 |
| in ia d ie ( d is ) In te t te M re s a ss oc co m p an s e |
0 | 1. 1 9 3 |
n. a. |
| O he t t ts r no n- cu rr en as se |
2. 7 7 8 |
2. 4 8 4 |
-1 1 % |
| Cu t ts en as se rr |
2 1. 0 8 2 |
2 0. 2 3 0 |
-4 % |
| Tr de de iv b le ra a ec e a s r |
4. 2 2 2 |
4. 4. 5 6 1 |
8 % |
| f O he in ia l a t ts an c ss e r |
8. 5 4 0 |
7. 2 7 7 |
-1 5 % |
| f: t he Se it ies re o cu r |
8. 5 4 0 |
6. 0 3 7 |
-2 9 % |
| Ca h d h iv le ts s an ca s eq u a n |
7. 7 1 8 |
7. 6 3 0 |
-1 % |
| O he t t ts r c re n as se ur |
6 0 2 |
7 6 2 |
2 7 % |
| A S S E T S |
5 0. 9 5 5 |
5 1. 3 1 4 |
1 % |
| i i l Eq ty ta u c ap |
3 2. 6 0 7 |
3 3. 2 8 1 |
2 % |
| Su bs i be d i l ta cr ca p |
1. 8 2 0 |
1. 8 2 0 |
0 % |
| Ca i l r ta p es er ve |
2 8. 4 6 5 |
2 8. 5 1 2 |
0 % |
| Tr k to ea su s c ry |
-4 1 5 6 |
3. 7 8 9 - |
-9 % |
| Re in d in ta e ea rn g s |
4 9 . 9 3 |
4 6 . 9 8 |
1 % |
| he l O t Eq i ty i ta r u c ap |
1. 5 3 9 |
1. 5 9 9 |
4 % |
| l ia b i l i ie N t t on -c ur re n s |
7. 0 2 5 |
7. 7 1 3 |
1 0 % |
| he f l l b l O t in ia ia i i t ie r an c s |
8 6. 5 9 |
6. 6 9 0 |
1 % |
| O he l b l t t ia i i t ie r no n- cu rr en s |
2 4 7 |
0 2 3 1. |
0 % 1 4 |
| Cu l ia b i l i ie t t rr en s |
3 2 3 1 1. |
0. 3 1 4 7 |
-8 % |
| de b le Tr a p ay a s |
1. 1 2 1 |
9 0 5 |
-1 9 % |
| O he f in ia l l ia b i l i ie t t r an c s |
7. 4 7 8 |
6. 8 9 4 |
-8 % |
| O he l ia b i l i ie t t t re n r c ur s |
2. 7 2 4 |
2. 6 7 4 |
-2 % |
| Eq ity io t u ra |
6 4 % |
6 5 % |
|
| Re tu ity rn o n eq u |
0 % |
% 1 |
|
| De iat ion te p re c ra |
2 % |
2 % |
|
| de bt ity io to t e q u ra |
5 6 % |
5 5 % |
MeVis Medical Solutions AG
November 23, 2010 German Equity Forum Dr. Robert Hannemann 24
Contact: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.